X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1073) 1073
Publication (77) 77
Book Review (33) 33
Book / eBook (19) 19
Book Chapter (10) 10
Conference Proceeding (4) 4
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (795) 795
animals (667) 667
mice (449) 449
oncology (390) 390
immunotoxins - therapeutic use (330) 330
immunotoxins - pharmacokinetics (328) 328
female (320) 320
index medicus (283) 283
immunotoxins (220) 220
antibodies, monoclonal - therapeutic use (214) 214
cancer (204) 204
immunotoxin (201) 201
mice, nude (187) 187
male (173) 173
tissue distribution (163) 163
immunotoxins - pharmacology (162) 162
pharmacology & pharmacy (147) 147
mice, inbred balb c (138) 138
antibodies, monoclonal - pharmacokinetics (136) 136
immunotherapy (133) 133
immunotoxins - metabolism (125) 125
monoclonal-antibody (125) 125
therapy (124) 124
tumor cells, cultured (123) 123
immunotoxins - administration & dosage (122) 122
immunotoxins - immunology (117) 117
cell line, tumor (110) 110
antibodies (105) 105
immunology (105) 105
immunotoxins - toxicity (103) 103
antibodies, monoclonal - immunology (101) 101
monoclonal-antibodies (101) 101
rats (100) 100
immunotoxins - chemistry (95) 95
antineoplastic agents - therapeutic use (92) 92
neoplasm transplantation (91) 91
radioimmunotherapy (91) 91
monoclonal antibodies (85) 85
phase-i (84) 84
antitumor-activity (83) 83
hematology (83) 83
transplantation, heterologous (83) 83
tumors (83) 83
adult (82) 82
expression (81) 81
middle aged (81) 81
xenograft model antitumor assays (81) 81
antibodies, monoclonal - administration & dosage (80) 80
biochemistry & molecular biology (77) 77
pharmacokinetics (76) 76
antineoplastic agents - pharmacokinetics (74) 74
care and treatment (74) 74
phase-i trial (74) 74
recombinant immunotoxin (74) 74
proteins (73) 73
cytotoxicity (72) 72
aged (71) 71
cells (71) 71
immunotoxins - adverse effects (69) 69
neoplasms - drug therapy (68) 68
antibodies, monoclonal - metabolism (67) 67
ribosome inactivating proteins, type 1 (67) 67
pseudomonas exotoxin (66) 66
toxicity (66) 66
chemotherapy (65) 65
antibodies, monoclonal (64) 64
antineoplastic agents - administration & dosage (63) 63
clinical trials as topic (63) 63
antibodies, monoclonal - pharmacology (61) 61
health aspects (61) 61
ricin-a-chain (61) 61
in-vitro (60) 60
research (60) 60
cell survival - drug effects (59) 59
antibody-toxin conjugates (58) 58
antineoplastic agents - pharmacology (57) 57
neoplasms - therapy (56) 56
article (54) 54
antibody (52) 52
antigens, neoplasm - immunology (52) 52
dose-response relationship, drug (52) 52
drug delivery systems (52) 52
monoclonal antibody (51) 51
recombinant fusion proteins - therapeutic use (51) 51
leukemia (50) 50
ricin - pharmacokinetics (50) 50
medicine, research & experimental (49) 49
mice, scid (49) 49
recombinant fusion proteins - pharmacokinetics (49) 49
ricin (49) 49
treatment outcome (49) 49
toxicology (48) 48
antigens, cd - immunology (47) 47
molecular sequence data (46) 46
acute myeloid-leukemia (45) 45
cell line (45) 45
half-life (45) 45
medicine & public health (45) 45
immunotoxins - genetics (44) 44
medicine (44) 44
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1080) 1080
Japanese (10) 10
Chinese (5) 5
Russian (2) 2
French (1) 1
German (1) 1
Persian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2085 - 2093
Journal Article
The AAPS Journal, ISSN 1550-7416, 9/2016, Volume 18, Issue 5, pp. 1117 - 1130
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 5/2012, Volume 52, Issue 5, pp. 691 - 703
Trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate in development for treatment of HER2-positive cancers. T-DM1 has been tested as a... 
trastuzumab | trastuzumab emtansine | antibody‐drug conjugate | T‐DM1 | population pharmacokinetics | T-DM1 | antibody-drug conjugate | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | Body Weight | Breast Neoplasms - immunology | Humans | Middle Aged | Immunotoxins - adverse effects | Receptor, ErbB-2 - metabolism | Drug Dosage Calculations | Antibodies, Monoclonal, Humanized - administration & dosage | Immunotoxins - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Biomarkers, Tumor - metabolism | Tubulin Modulators - administration & dosage | Adult | Female | Receptor, ErbB-2 - immunology | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Tubulin Modulators - adverse effects | Drug Administration Schedule | Maytansine - analogs & derivatives | Tubulin Modulators - pharmacokinetics | Linear Models | Treatment Outcome | Tumor Burden | Breast Neoplasms - drug therapy | Maximum Tolerated Dose | Maytansine - administration & dosage | Aspartate Aminotransferases - blood | Breast Neoplasms - pathology | Models, Biological | Maytansine - pharmacokinetics | Breast Neoplasms - blood | Protein Binding | Immunotoxins - pharmacokinetics | Infusions, Intravenous | Biomarkers, Tumor - immunology | Trastuzumab | Serum Albumin - metabolism | Care and treatment | Breast cancer | Research | Drug therapy | Pharmacokinetics | Population | Metastasis | Drug dosages
Journal Article
Cancer Research, ISSN 0008-5472, 03/2009, Volume 69, Issue 6, pp. 2358 - 2364
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 398 - 405
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3792 - 3800
Immunotoxins based on Pseudomonas exotoxin A (PE) are promising anticancer agents that combine a variable fragment (Fv) from an antibody to a tumor-associated... 
Immunoglobulin Variable Region - adverse effects | Virulence Factors - genetics | Exotoxins - pharmacokinetics | Humans | Antibodies, Monoclonal - adverse effects | Bacterial Toxins - pharmacokinetics | Immunotoxins - adverse effects | Immunotoxins - pharmacology | Endosomes - metabolism | Exotoxins - adverse effects | Lysosomes - metabolism | Virulence Factors - pharmacokinetics | ADP Ribose Transferases - pharmacokinetics | Bacterial Toxins - genetics | Female | Sialic Acid Binding Ig-like Lectin 2 | ADP Ribose Transferases - adverse effects | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Clinical Trials as Topic | Exotoxins - pharmacology | Bacterial Toxins - adverse effects | Xenograft Model Antitumor Assays | ADP Ribose Transferases - genetics | Antibodies, Monoclonal - genetics | Immunotoxins - genetics | Animals | Bacterial Toxins - pharmacology | Mice, Nude | ADP Ribose Transferases - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Exotoxins - genetics | Immunoglobulin Variable Region - pharmacology | Immunoglobulin Variable Region - genetics | Immunotoxins - pharmacokinetics | Mice | Mice, Inbred BALB C | Virulence Factors - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mutation | Virulence Factors - pharmacology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Cancer, ISSN 0008-543X, 12/2012, Volume 118, Issue 23, pp. 5733 - 5740
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2011, Volume 10, Issue 10, pp. 1829 - 1838
A novel anticancer agent was constructed by fusing a gene encoding the scFV that targets both glycosylated and unglycosylated forms of CD133 to a gene fragment... 
RECOMBINANT IMMUNOTOXIN | STEM-CELLS | IMMUNOGENICITY | ONCOLOGY | IN-VIVO | DIFFERENTIATION | IDENTIFICATION | AC133 | CARCINOMA | LIGAND-DIRECTED TOXIN | CD133 | Antigens, CD - immunology | Virulence Factors - genetics | Recombinant Fusion Proteins - pharmacology | Antigens, CD - biosynthesis | Neoplastic Stem Cells - drug effects | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Exotoxins - pharmacokinetics | Humans | Bacterial Toxins - pharmacokinetics | Peptides - genetics | Immunotoxins - pharmacology | Antigens, CD - genetics | Head and Neck Neoplasms - metabolism | Transfection | Virulence Factors - pharmacokinetics | ADP Ribose Transferases - pharmacokinetics | Bacterial Toxins - genetics | Female | Glycoproteins - genetics | Cell Survival - drug effects | Cell Growth Processes - drug effects | Peptides - immunology | Head and Neck Neoplasms - drug therapy | Exotoxins - pharmacology | AC133 Antigen | Immunoglobulin Fragments - pharmacology | Head and Neck Neoplasms - pathology | Glycoproteins - biosynthesis | Xenograft Model Antitumor Assays | ADP Ribose Transferases - genetics | Glycoproteins - immunology | Immunotoxins - genetics | Animals | Carcinoma, Squamous Cell - drug therapy | Bacterial Toxins - pharmacology | Mice, Nude | ADP Ribose Transferases - pharmacology | Recombinant Fusion Proteins - pharmacokinetics | Exotoxins - genetics | Cell Line, Tumor | Recombinant Fusion Proteins - genetics | Head and Neck Neoplasms - genetics | Immunoglobulin Fragments - genetics | Immunotoxins - pharmacokinetics | Mice | Mice, Inbred BALB C | Virulence Factors - pharmacology | xenograft model | cancer stem cells | head and neck cancer | pseudomonas exotoxin
Journal Article